LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 11

Search options

  1. Article ; Online: INAD and Duchenne muscular dystrophy, two ends of the iPLA2β spectrum.

    Offringa-Hup, Annette

    Medical hypotheses

    2020  Volume 137, Page(s) 109589

    Abstract: Infantile neuroaxonal dystrophy (INAD) and Duchenne muscular dystrophy (DMD) are two deadly neuromuscular degenerative diseases of childhood. Knowledge on their pathophysiological mechanisms may direct us towards treatment or a cure. Although these ... ...

    Abstract Infantile neuroaxonal dystrophy (INAD) and Duchenne muscular dystrophy (DMD) are two deadly neuromuscular degenerative diseases of childhood. Knowledge on their pathophysiological mechanisms may direct us towards treatment or a cure. Although these diseases are caused by two totally different gene-mutations and cause different clinical pictures, in this article I propose a common disease mechanism in the two. This common mechanism is induced by defects in the response to cellular stress and injury. THE HYPOTHESIS: Depletion of iPLA2β in INAD and increased activity of iPLA2β in DMD eventually lead to similar defects in the response to cell stress and injury. According to this hypothesis, the depletion of iPLA2β in INAD primarily blocks repair mechanisms by the inability to form a mitochondrial permeability transition pore (PTP). Forming of the PTP is necessary to release mitochondrial coenzyme A (CoA) into the cytoplasm for activation of palmitoylation and massive endocytosis as a repair response. In DMD the increased activity of iPLA2β causes exhaustion of the stress signalling cascade by increased and prolonged PTP opening. Continuous leaking of mitochondrial CoA through the PTP leads to the inability of the cell to build a sufficient mitochondrial:cytoplasmic CoA gradient, also causing insufficient release of mitochondrial CoA as a response to cell stress and injury. Decreased palmitoylation capacity and decreased endocytosis and membrane remodelling are implicated in proven pathophysiological mechanisms in INAD and DMD. The described mechanism in INAD and DMD, may be considered a common mechanism of repair in case of cell stress and injury. Beside their role in INAD and DMD, they may therefore be implicated in other neurodegenerative diseases as well. Available research shows involvement of iPLA2β in other neurodegenerative diseases. We might be able to divide neurodegenerative diseases in "INAD-like disease-mechanism" or "DMD-like disease-mechanism", depending on decreased or increased iPLA2β activity.
    MeSH term(s) Animals ; Disease Models, Animal ; Mitochondria ; Muscular Dystrophy, Duchenne ; Neuroaxonal Dystrophies ; Neurodegenerative Diseases
    Language English
    Publishing date 2020-01-23
    Publishing country United States
    Document type Journal Article
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2020.109589
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Alzheimer's disease: The derailed repair hypothesis.

    Offringa-Hup, Annette

    Medical hypotheses

    2019  Volume 136, Page(s) 109516

    Abstract: A lot of research has been done on Alzheimer's disease, especially focused on factors like amyloid beta, ApoE and tau-protein. However, a complete theory on the disease mechanism of AD, including and connecting all known pathological elements of AD in a ... ...

    Abstract A lot of research has been done on Alzheimer's disease, especially focused on factors like amyloid beta, ApoE and tau-protein. However, a complete theory on the disease mechanism of AD, including and connecting all known pathological elements of AD in a conceivable context and order of occurrence, is still lacking. In this article I describe a hypothesis on the entire pathophysiology of Alzheimer's disease, based on the most wellknown pathological elements in AD, filling the gaps with hypothetical mechanisms. This proposed mechanism of derailed repair starts with an insufficiently increased level of injury signalling in the axon by ApoE, DLK, APP, BACE-1, Aβ and iPLA2β, followed by an excessive repair response induced by opening of the mitochondrial permeability transition pore, release of mitochondrial CoA and activation of palmitoylation and massive endocytosis. Excessive compounds, associated with injury signalling and repair, start to accumulate, adding to axonal injury. This increased activation of the repair mechanism causes exhaustion of the repair response by lack of mitochondrial CoA. A vicious circle of increased injury signalling and insufficient repair ensues. Based on this hypothesis, I propose possible markers for early diagnosis and disease-modifying treatments for Alzheimer's disease.
    MeSH term(s) Alzheimer Disease/physiopathology ; Alzheimer Disease/therapy ; Amyloid Precursor Protein Secretases/metabolism ; Apolipoproteins E/metabolism ; Aspartic Acid Endopeptidases/metabolism ; Axons/pathology ; Brain Injuries/physiopathology ; Brain Injuries/therapy ; Endocytosis ; Group VI Phospholipases A2/metabolism ; Homeostasis ; Humans ; Mitochondria/metabolism ; Models, Theoretical
    Chemical Substances ApoE protein, human ; Apolipoproteins E ; Group VI Phospholipases A2 (EC 3.1.1.4) ; PLA2G6 protein, human (EC 3.1.1.4) ; Amyloid Precursor Protein Secretases (EC 3.4.-) ; Aspartic Acid Endopeptidases (EC 3.4.23.-) ; BACE1 protein, human (EC 3.4.23.46)
    Language English
    Publishing date 2019-12-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2019.109516
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Clinical implications of vitamin B

    Offringa, Annette K / Bourgonje, Arno R / Schrier, Matthew S / Deth, Richard C / van Goor, Harry

    Trends in molecular medicine

    2021  Volume 27, Issue 10, Page(s) 931–934

    Abstract: ... Vitamin ... ...

    Abstract Vitamin B
    MeSH term(s) Cobalt ; Humans ; Methylmalonyl-CoA Mutase/genetics ; Methylmalonyl-CoA Mutase/metabolism ; Oxidation-Reduction ; Vitamin B 12/metabolism ; Vitamin B 12/pharmacology ; Vitamins
    Chemical Substances Vitamins ; Cobalt (3G0H8C9362) ; Methylmalonyl-CoA Mutase (EC 5.4.99.2) ; Vitamin B 12 (P6YC3EG204)
    Language English
    Publishing date 2021-07-23
    Publishing country England
    Document type Journal Article
    ZDB-ID 2036490-8
    ISSN 1471-499X ; 1471-4914
    ISSN (online) 1471-499X
    ISSN 1471-4914
    DOI 10.1016/j.molmed.2021.07.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: The Disease-Modifying Role of Taurine and Its Therapeutic Potential in Coronavirus Disease 2019 (COVID-19).

    van Eijk, Larissa E / Offringa, Annette K / Bernal, Maria-Elena / Bourgonje, Arno R / van Goor, Harry / Hillebrands, Jan-Luuk

    Advances in experimental medicine and biology

    2022  Volume 1370, Page(s) 3–21

    Abstract: Taurine is an amino sulfonic acid that is implicated in numerous physiological functions, including the regulation of oxidative stress, which plays an important role in coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome ... ...

    Abstract Taurine is an amino sulfonic acid that is implicated in numerous physiological functions, including the regulation of oxidative stress, which plays an important role in coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), together with other pathophysiological processes. The recent finding of decreased serum taurine levels in SARS-CoV-2-infected patients, in tandem with its potential modulatory role in COVID-19 due to its antiviral, antioxidant, anti-inflammatory, and vascular-related effects, provides a rationale for considering taurine as a beneficial supplement in patients suffering from COVID-19. Here, we reviewed the potential disease-modifying effects of taurine and combined these with the current knowledge on COVID-19 to clarify the potential role of taurine in this respiratory disease.
    MeSH term(s) Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; Humans ; SARS-CoV-2 ; Taurine/pharmacology ; Taurine/therapeutic use
    Chemical Substances Antiviral Agents ; Taurine (1EQV5MLY3D)
    Language English
    Publishing date 2022-07-26
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2214-8019 ; 0065-2598
    ISSN (online) 2214-8019
    ISSN 0065-2598
    DOI 10.1007/978-3-030-93337-1_1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.

    Offringa, Annette / Montijn, Roy / Singh, Sandeep / Paul, Martin / Pinto, Yigal M / Pinto-Sietsma, Sara-Joan

    European heart journal. Cardiovascular pharmacotherapy

    2020  Volume 6, Issue 5, Page(s) 317–325

    Abstract: The SARS-CoV-2 pandemic is a healthcare crisis caused by insufficient knowledge applicable to effectively combat the virus. Therefore, different scientific discovery strategies need to be connected, to generate a rational treatment which can be made ... ...

    Abstract The SARS-CoV-2 pandemic is a healthcare crisis caused by insufficient knowledge applicable to effectively combat the virus. Therefore, different scientific discovery strategies need to be connected, to generate a rational treatment which can be made available as rapidly as possible. This relies on a solid theoretical understanding of the mechanisms of SARS-CoV-2 infection and host responses, which is coupled to the practical experience of clinicians that are treating patients. Because SARS-CoV-2 enters the cell by binding to angiotensin-converting enzyme 2 (ACE2), targeting ACE2 to prevent such binding seems an obvious strategy to combat infection. However, ACE2 performs its functions outside the cell and was found to enter the cell only by angiotensin II type 1 receptor (AT1R)-induced endocytosis, after which ACE2 is destroyed. This means that preventing uptake of ACE2 into the cell by blocking AT1R would be a more logical approach to limit entry of SARS-CoV-2 into the cell. Since ACE2 plays an important protective role in maintaining key biological processes, treatments should not disrupt the functional capacity of ACE2, to counterbalance the negative effects of the infection. Based on known mechanisms and knowledge of the characteristics of SARS-CoV we propose the hypothesis that the immune system facilitates SARS-CoV-2 replication which disrupts immune regulatory mechanisms. The proposed mechanism by which SARS-CoV-2 causes disease immediately suggests a possible treatment, since the AT1R is a key player in this whole process. AT1R antagonists appear to be the ideal candidate for the treatment of SARS-CoV-2 infection. AT1R antagonists counterbalance the negative consequences of angiotesnin II and, in addition, they might even be involved in preventing the cellular uptake of the virus without interfering with ACE2 function. AT1R antagonists are widely available, cheap, and safe. Therefore, we propose to consider using AT1R antagonists in the treatment of SARS-CoV-2.
    MeSH term(s) Angiotensin II/metabolism ; Angiotensin II Type 1 Receptor Blockers/therapeutic use ; Animals ; Antiviral Agents/therapeutic use ; Betacoronavirus/drug effects ; Betacoronavirus/immunology ; Betacoronavirus/pathogenicity ; COVID-19 ; Coronavirus Infections/drug therapy ; Coronavirus Infections/immunology ; Coronavirus Infections/metabolism ; Coronavirus Infections/virology ; Endocytosis/drug effects ; Host-Pathogen Interactions ; Humans ; Pandemics ; Peptidyl-Dipeptidase A/metabolism ; Peptidyl-Dipeptidase A/therapeutic use ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/immunology ; Pneumonia, Viral/metabolism ; Pneumonia, Viral/virology ; Renin-Angiotensin System/drug effects ; SARS-CoV-2 ; Virus Internalization/drug effects ; COVID-19 Drug Treatment
    Chemical Substances Angiotensin II Type 1 Receptor Blockers ; Antiviral Agents ; Angiotensin II (11128-99-7) ; ACE protein, human (EC 3.4.15.1) ; Peptidyl-Dipeptidase A (EC 3.4.15.1)
    Keywords covid19
    Language English
    Publishing date 2020-05-29
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2808613-2
    ISSN 2055-6845 ; 2055-6837
    ISSN (online) 2055-6845
    ISSN 2055-6837
    DOI 10.1093/ehjcvp/pvaa053
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019.

    Bourgonje, Arno R / Offringa, Annette K / van Eijk, Larissa E / Abdulle, Amaal E / Hillebrands, Jan-Luuk / van der Voort, Peter H J / van Goor, Harry / van Hezik, Ed J

    Antioxidants & redox signaling

    2021  Volume 35, Issue 14, Page(s) 1207–1225

    Abstract: Significance: ...

    Abstract Significance:
    MeSH term(s) Acetylcysteine/metabolism ; COVID-19/metabolism ; Humans ; Hydrogen Sulfide/metabolism ; Oxidation-Reduction
    Chemical Substances Acetylcysteine (WYQ7N0BPYC) ; Hydrogen Sulfide (YY9FVM7NSN)
    Language English
    Publishing date 2021-03-25
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 1483836-9
    ISSN 1557-7716 ; 1523-0864
    ISSN (online) 1557-7716
    ISSN 1523-0864
    DOI 10.1089/ars.2020.8247
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system

    Offringa, Annette / Montijn, Roy / Singh, Sandeep / Paul, Martin / Pinto, Yigal M / Pinto-Sietsma, Sara-Joan

    Eur Heart J Cardiovasc Pharmacother

    Abstract: The SARS-CoV-2 pandemic is a healthcare crisis caused by insufficient knowledge applicable to effectively combat the virus. Therefore, different scientific discovery strategies need to be connected, to generate a rational treatment which can be made ... ...

    Abstract The SARS-CoV-2 pandemic is a healthcare crisis caused by insufficient knowledge applicable to effectively combat the virus. Therefore, different scientific discovery strategies need to be connected, to generate a rational treatment which can be made available as rapidly as possible. This relies on a solid theoretical understanding of the mechanisms of SARS-CoV-2 infection and host responses, which is coupled to the practical experience of clinicians that are treating patients. Because SARS-CoV-2 enters the cell by binding to angiotensin-converting enzyme 2 (ACE2), targeting ACE2 to prevent such binding seems an obvious strategy to combat infection. However, ACE2 performs its functions outside the cell and was found to enter the cell only by angiotensin II type 1 receptor (AT1R)-induced endocytosis, after which ACE2 is destroyed. This means that preventing uptake of ACE2 into the cell by blocking AT1R would be a more logical approach to limit entry of SARS-CoV-2 into the cell. Since ACE2 plays an important protective role in maintaining key biological processes, treatments should not disrupt the functional capacity of ACE2, to counterbalance the negative effects of the infection. Based on known mechanisms and knowledge of the characteristics of SARS-CoV we propose the hypothesis that the immune system facilitates SARS-CoV-2 replication which disrupts immune regulatory mechanisms. The proposed mechanism by which SARS-CoV-2 causes disease immediately suggests a possible treatment, since the AT1R is a key player in this whole process. AT1R antagonists appear to be the ideal candidate for the treatment of SARS-CoV-2 infection. AT1R antagonists counterbalance the negative consequences of angiotesnin II and, in addition, they might even be involved in preventing the cellular uptake of the virus without interfering with ACE2 function. AT1R antagonists are widely available, cheap, and safe. Therefore, we propose to consider using AT1R antagonists in the treatment of SARS-CoV-2.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #401349
    Database COVID19

    Kategorien

  8. Article ; Online: The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication

    Offringa, Annette / Montijn, Roy / Singh, Sandeep / Paul, Martin / Pinto, Yigal M / Pinto-Sietsma*, Sara-Joan

    European Heart Journal - Cardiovascular Pharmacotherapy

    possible treatment options related to the renin–angiotensin system

    2020  Volume 6, Issue 5, Page(s) 317–325

    Abstract: Abstract The SARS-CoV-2 pandemic is a healthcare crisis caused by insufficient knowledge applicable to effectively combat the virus. Therefore, different scientific discovery strategies need to be connected, to generate a rational treatment which can be ... ...

    Abstract Abstract The SARS-CoV-2 pandemic is a healthcare crisis caused by insufficient knowledge applicable to effectively combat the virus. Therefore, different scientific discovery strategies need to be connected, to generate a rational treatment which can be made available as rapidly as possible. This relies on a solid theoretical understanding of the mechanisms of SARS-CoV-2 infection and host responses, which is coupled to the practical experience of clinicians that are treating patients. Because SARS-CoV-2 enters the cell by binding to angiotensin-converting enzyme 2 (ACE2), targeting ACE2 to prevent such binding seems an obvious strategy to combat infection. However, ACE2 performs its functions outside the cell and was found to enter the cell only by angiotensin II type 1 receptor (AT1R)-induced endocytosis, after which ACE2 is destroyed. This means that preventing uptake of ACE2 into the cell by blocking AT1R would be a more logical approach to limit entry of SARS-CoV-2 into the cell. Since ACE2 plays an important protective role in maintaining key biological processes, treatments should not disrupt the functional capacity of ACE2, to counterbalance the negative effects of the infection. Based on known mechanisms and knowledge of the characteristics of SARS-CoV we propose the hypothesis that the immune system facilitates SARS-CoV-2 replication which disrupts immune regulatory mechanisms. The proposed mechanism by which SARS-CoV-2 causes disease immediately suggests a possible treatment, since the AT1R is a key player in this whole process. AT1R antagonists appear to be the ideal candidate for the treatment of SARS-CoV-2 infection. AT1R antagonists counterbalance the negative consequences of angiotesnin II and, in addition, they might even be involved in preventing the cellular uptake of the virus without interfering with ACE2 function. AT1R antagonists are widely available, cheap, and safe. Therefore, we propose to consider using AT1R antagonists in the treatment of SARS-CoV-2.
    Keywords covid19
    Language English
    Publisher Oxford University Press (OUP)
    Publishing country uk
    Document type Article ; Online
    ZDB-ID 2808613-2
    ISSN 2055-6845 ; 2055-6837
    ISSN (online) 2055-6845
    ISSN 2055-6837
    DOI 10.1093/ehjcvp/pvaa053
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: COVID-19: immunopathology, pathophysiological mechanisms, and treatment options.

    van Eijk, Larissa E / Binkhorst, Mathijs / Bourgonje, Arno R / Offringa, Annette K / Mulder, Douwe J / Bos, Eelke M / Kolundzic, Nikola / Abdulle, Amaal E / van der Voort, Peter Hj / Olde Rikkert, Marcel Gm / van der Hoeven, Johannes G / den Dunnen, Wilfred Fa / Hillebrands, Jan-Luuk / van Goor, Harry

    The Journal of pathology

    2021  Volume 254, Issue 4, Page(s) 307–331

    Abstract: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally despite the worldwide implementation of preventive measures to combat the disease. Although most COVID-19 cases are ... ...

    Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread globally despite the worldwide implementation of preventive measures to combat the disease. Although most COVID-19 cases are characterised by a mild, self-limiting disease course, a considerable subset of patients develop a more severe condition, varying from pneumonia and acute respiratory distress syndrome (ARDS) to multi-organ failure (MOF). Progression of COVID-19 is thought to occur as a result of a complex interplay between multiple pathophysiological mechanisms, all of which may orchestrate SARS-CoV-2 infection and contribute to organ-specific tissue damage. In this respect, dissecting currently available knowledge of COVID-19 immunopathogenesis is crucially important, not only to improve our understanding of its pathophysiology but also to fuel the rationale of both novel and repurposed treatment modalities. Various immune-mediated pathways during SARS-CoV-2 infection are relevant in this context, which relate to innate immunity, adaptive immunity, and autoimmunity. Pathological findings in tissue specimens of patients with COVID-19 provide valuable information with regard to our understanding of pathophysiology as well as the development of evidence-based treatment regimens. This review provides an updated overview of the main pathological changes observed in COVID-19 within the most commonly affected organ systems, with special emphasis on immunopathology. Current management strategies for COVID-19 include supportive care and the use of repurposed or symptomatic drugs, such as dexamethasone, remdesivir, and anticoagulants. Ultimately, prevention is key to combat COVID-19, and this requires appropriate measures to attenuate its spread and, above all, the development and implementation of effective vaccines. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.
    MeSH term(s) Adaptive Immunity/drug effects ; Adaptive Immunity/immunology ; Antiviral Agents/pharmacology ; COVID-19/pathology ; COVID-19/virology ; Humans ; Immunity, Innate/drug effects ; Immunity, Innate/immunology ; SARS-CoV-2/pathogenicity ; United Kingdom ; COVID-19 Drug Treatment
    Chemical Substances Antiviral Agents
    Language English
    Publishing date 2021-03-25
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 3119-7
    ISSN 1096-9896 ; 0022-3417
    ISSN (online) 1096-9896
    ISSN 0022-3417
    DOI 10.1002/path.5642
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Discontinuation of Antihypertensive Medications on the Outcome of Hospitalized Patients With Severe Acute Respiratory Syndrome-Coronavirus 2.

    Singh, Sandeep / Offringa-Hup, Annette K / Logtenberg, Susan J J / Van der Linden, Paul D / Janssen, Wilbert M T / Klein, Hubertina / Waanders, Femke / Simsek, Suat / de Jager, Cornelis P C / Smits, Paul / van der Feltz, Machteld / Jan Beumer, Gerrit / Widrich, Christine / Nap, Martijn / Pinto-Sietsma, Sara-Joan

    Hypertension (Dallas, Tex. : 1979)

    2021  Volume 78, Issue 1, Page(s) 165–173

    Abstract: Figure: see text]. ...

    Abstract [Figure: see text].
    MeSH term(s) Adrenergic beta-Antagonists/pharmacology ; Adrenergic beta-Antagonists/therapeutic use ; Adult ; Aged ; Aged, 80 and over ; Angiotensin Receptor Antagonists/pharmacology ; Angiotensin Receptor Antagonists/therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Antihypertensive Agents/pharmacology ; Antihypertensive Agents/therapeutic use ; COVID-19/complications ; COVID-19/mortality ; COVID-19/physiopathology ; Female ; Hospitalization ; Humans ; Hypertension/complications ; Hypertension/drug therapy ; Male ; Middle Aged ; Renin-Angiotensin System/drug effects ; Retrospective Studies ; SARS-CoV-2 ; Treatment Outcome ; Withholding Treatment
    Chemical Substances Adrenergic beta-Antagonists ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Antihypertensive Agents
    Language English
    Publishing date 2021-06-09
    Publishing country United States
    Document type Journal Article ; Observational Study
    ZDB-ID 423736-5
    ISSN 1524-4563 ; 0194-911X ; 0362-4323
    ISSN (online) 1524-4563
    ISSN 0194-911X ; 0362-4323
    DOI 10.1161/HYPERTENSIONAHA.121.17328
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top